Endoluxe Named to the 2022 CB Insights’ Digital Health 150 List

December 7, 2022

CB Insights today named Endoluxe to its fourth-annual Digital Health 150, showcasing the 150 most promising private digital health companies of 2022. 

"From reimagining clinical care, to leveraging tech like AR/VR to improve surgical training, this year’s DigitalHealth 150 winners are transforming the future of healthcare with digital technology,” said Brian Lee, SVP of CBInsights’ Intelligence Unit. “This increasingly global cohort, representing more than 18countries across five continents, is not only driving better patient outcomes, but making healthcare more accessible. We are excited to follow the meaningful impact and continued success of this year’s winners.”

“We are extremely pleased to be named to this year’s list as one of only nine companies in computer-aided imaging,” said Devon Bream, CEO of Endoluxe. “This is just further affirmation that our unique approach to endoscopic visualization is the direction of the future. Our development of edge artificial intelligence that helps surgeons with real-time clinical insights will continue to advance endoscopic technology and lead to dramatically better patient outcomes.”

Utilizing the CB Insights platform, the research team selected these 150 winners from a pool of over 13,000 private companies, including applicants and nominees. They were chosen based on factors including R&D activity, proprietary Mosaic scores, market potential, business relationships, investor profile, news sentiment analysis, competitive landscape, team strength, and tech novelty. The research team also reviewed over 3,000  Analyst Briefings submitted by applicants.

The Endoluxe Visualization System is a handheld, wireless, portable orb containing an HD camera and LED light source that can be attached to rigid or flexible analog endoscopes. The orb is small, lightweight and self-contained, with around touchscreen that shows video onboard and contains a user interface with device controls. It’s also a smart device with the ability to wirelessly stream video to any HDMI-equipped display, or to remote destinations for teleconsulting or educational purposes. Endoluxe is developing artificial intelligence and machine learning applications that will provide doctors and medics with real-time clinical insights to improve patient care. All of this comes at a price point that is approximately one-quarter that of legacy tower-based endoscopic camera systems.

Quick facts on the 2022 DigitalHealth 150:

●      Equity funding and deals: Since 2017, this year's DigitalHealth 150 winners have raised around $5.6B in equity funding across 378 deals.This includes approximately $1.6B raised across 85 deals in 2022 YTD alone.

●      Unicorns: This year's list includes only 5 unicorns with a $1B+ valuation, around 3% of the total list. For comparison, last year's list contained 17.This tracks with a broader drop in new unicorns across sectors in 2022

●     Global Reach: Winners in this year'sDigital Health 150 span 18 countries across 5 continents. A quarter (25%) are headquartered outside of the US — the most in the history of our list. While the US still leads, the UK comes in second with 9 winners, followed by Canada with 5 and Brazil with 3.

 About CB Insights

CB Insights builds software that enables the world's best companies to discover, understand, and make technology decisions with confidence. By marrying data, expert insights, and work management tools, clients manage their end-to-end technology decision-making process on CBInsights. To learn more, please visit www.cbinsights.com. 



About Endoluxe
Endoluxe is a world-class endoscopic video imaging organization based in the United States, with worldwide distribution of its medical industry design award-winning Endoluxe Orb. The company is focused on reducing costs of legacy video platforms, enhancing procedure adoption, and improving patient outcomes through better therapy application. Endoluxe is committed to being a vendor-agnostic platform that allows customers to utilize their existing investment in traditional scopes and supporting devices — while taking advantage of future technological advancements using our portable, integrated and feature-laden platform at 1/4th the cost of legacy products. More information can be found at Endoluxe.com.